Posted by Michael Wonder on 05 Jun 2019
GSK's Nucala wins European panel thumbs-up for self-administration
4 June 2019 - GlaxoSmithKline said on Tuesday it had won marketing approval from a EM) panel for its Nucala drug to be self-administered to treat severe asthma.
EMA’s human medicines committee (CHMP) cleared the drug mepolizumab, branded as Nucala, and recommended two new methods for administering the drug to patients with severe eosinophils asthma.
